Pfizer (NYSE:PFE) announced today that it entered into an agreement to acquire biopharmaceutical company ReViral.
ReViral discovers, develops and commercializes novel antiviral therapeutics designed to target respiratory syncytial virus (RSV).
“At Pfizer, we have a strong heritage in, and commitment to, fighting infectious diseases, most recently evidenced by our delivery of the first authorized vaccine and oral therapy to combat COVID-19,” Pfizer Chairperson and CEO Albert Bourla said in a news release. “We’re continuing to grow our pipeline – through our own research-and-development efforts, such as our investigational RSV vaccine programs, as well as strategic investments in companies like ReViral – with a focus on end-to-end capabilities to help protect patients from severe illness, hospitalization, and death.”
ReViral’s portfolio includes the sisunatovir oral inhibitor for blocking the fusion of the RSV virus to the host cell. Sisunatovir has …